Stay updated with breaking news from Bartp Leroy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
RTP gene therapy startup Opus Genetics has acquired the rights to two pre-clinical product candidates to treat inherited retinal diseases from New Jersey biopharm company Iveric Bio.
Opus to advance preclinical development programs for BEST1- and RHO-related retinal diseases Opus Genetics, a patient-first, clinical-stage gene therapy company
When Iveric Bio established its gene therapy advisory committee recently, the move signaled the opening of a second front in its mission to treat retinal diseases for which there are no treatments.
Published: May 21, 2021 By Alex Keown Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers. AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she...